DOCSLIB.ORG

The Rb/E2F Pathway: Expanding Roles and Emerging Paradigms

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Rb/E2F Pathway: Expanding Roles and Emerging Paradigms Downloaded from genesdev.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW The Rb/E2F pathway: expanding roles and emerging paradigms J. William Harbour1,2 and Douglas C. Dean1,3 1Division of Molecular Oncology and 2Department of Ophthalmology and Visual Sciences, Washington University, St. Louis, Missouri 63110,USA Received April 21, 2000; revised version accepted July 17, 2000. The retinoblastoma gene was identified over a decade Rb; these proteins are required for the viruses to trans- ago as the first tumor suppressor. Although the gene was form cells (DeCaprio et al. 1988; Whyte et al. 1988; Dy- initially cloned as a result of its frequent mutation in the son et al. 1989). rare pediatric eye tumor, retinoblastoma (Friend et al. Rb function depends, at least in part, on interactions 1986; Fung et al. 1987; Lee et al. 1987), it is now thought with the E2F family of DNA-binding transcription fac- to play a fundamental role in cellular regulation and is tors (E2F) (Chellappan et al. 1991; Dyson 1998; Nevins the target of tumorigenic mutations in many cell types. 1998). E2F sites are found in the promoters of many The retinoblastoma gene encodes a 928–amino acid genes that are important for cell cycle progression, and phosphoprotein, Rb, which arrests cells in the G1 phase Rb appears to repress transcription of these genes (Weinberg 1995). Rb is phosphorylated and dephosphory- through its interaction with E2F (Blake and Azizkhan lated during the cell cycle; the hyperphosphorylated (in- 1989; Thalmeier et al. 1989; Dalton 1992; Ohtani et al. active) form predominates in proliferating cells, whereas 1995). Recent findings in the Rb/E2F field are clarifying the hypophosphorylated (active) form is generally more how this pathway regulates the transition from G1 to S abundant in quiescent or differentiating cells (Chen et al. phase at the molecular level. Other emerging results 1989). As a demonstration its tumor suppressor activity, show that this pathway also regulates other parts of the Rb was reintroduced into Rb-deficient tumor cells and it cell cycle and that it may even have roles beyond cell blocked several features of the malignant phenotype cycle control. In this article, we review the current un- (Huang et al. 1988). Mutations affecting the retinoblas- derstanding of the mechanism of action of Rb and its toma gene are frequently encountered, not only in reti- roles in cell cycle regulation, apoptosis, and develop- noblastoma but also in other cancers such as osteosar- ment. We refer readers to recent reviews by Bartek et al. coma, small cell lung cancer, prostate cancer, and breast (1997), Dyson (1998), Lipinski and Jacks (1999), and Sherr cancer (Friend et al. 1986; Fung et al. 1987; Harbour et al. and Roberts (1999) for additional in-depth analysis of the 1988; Lee et al. 1988; T’Ang et al. 1988; Bookstein et al. field and for historical perspectives. 1990). Indeed, children with hereditary retinoblastoma have Ն30-fold increased risk of developing a second, nonocular malignancy, especially bone and soft tissue Rb structure sarcomas in adolescence and cutaneous melanomas in Rb contains several functional domains. Domains A and adulthood (Eng et al. 1993; Moll et al. 1997). These sec- B are highly conserved from humans to plants, and they ond neoplasms occur almost exclusively in patients who interact with each other along an extended interdomain have germ-line mutations in the retinoblastoma gene. As interface to form the central “pocket” (Chow and Dean a further indication of its fundamental role in tumor sup- 1996; Lee et al. 1998), which is critical to the tumor- pression, Rb can be functionally inactivated by consti- suppressor function of Rb (Qin et al. 1992). The pocket is tutive hyperphosphorylation in tumors that do not have disrupted by most naturally occurring germ-line muta- mutations in the retinoblastoma gene (Sherr 1996). In tions in hereditary retinoblastoma patients (Harbour addition, DNA tumor viruses express oncoproteins, such 1998) and by most tumor-derived mutations (Horowitz as adenovirus E1A, SV40 large tumor antigen, and hu- et al. 1990). Viral oncoproteins and a number of endog- man papillomavirus (HPV) E7, that bind and inactivate enous Rb-binding proteins contain an LXCXE motif that allows them to bind Rb (Whyte et al. 1988; Dyson et al. 1989; Ludlow et al. 1989; Lee et al. 1998). The crystal 3Corresponding author. structure of the pocket in complex with an LXCXE pep- E-MAIL [email protected]; FAX (314) 747-2797. Article and publication are at www.genesdev.org/cgi/doi/10.1101/ tide revealed that the binding site for LXCXE is in do- gad.813200. main B (Lee et al. 1998). However, domain A is required GENES & DEVELOPMENT 14:2393–2409 © 2000 by Cold Spring Harbor Laboratory Press ISSN 0890-9369/00 $5.00; www.genesdev.org 2393 Downloaded from genesdev.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press Harbour and Dean for domain B to assume an active conformation, thus thereby block the antiapoptotic activity of MDM2 by explaining the conservation of both domains (Kim and preventing the degradation of p53 (Hsieh et al. 1999). Cho 1997; Lee et al. 1998). A number of endogenous Further work is needed to elucidate the role of these proteins that interact with Rb also contain an LXCXE- protein interactions involving the carboxy-terminal re- like sequence, including histone deacetylase (HDAC)-1 gion of Rb in vivo. and HDAC2, and the ATPase, BRG1, from the SWI/SNF The function of the amino-terminal region of Rb re- nucleosome remodeling complex (Dunaief et al. 1994; mains controversial. This region contains consensus cdk Brehm et al. 1998; Luo et al. 1998; Magnaghi et al. 1998). phosphorylation sites, which may regulate Rb activity The LXCXE binding site is the best characterized but when they are phosphorylated during the cell cycle. In not the only binding site in the pocket. E2Fs do not con- addition, the amino-terminal region interacts with sev- tain an LXCXE and thus bind Rb at a distinct site that eral proteins, including MCM7 (a replication licensing appears to involve points of contact in both the pocket factor; Sterner et al. 1998), a novel G2/M cycle-regulated and in the carboxy-terminal region (Huang et al. 1992; kinase (Sterner et al. 1995), and other proteins (Durfee et Lee et al. 1998). This allows E2F to recruit complexes al. 1994), but the function of these interactions is still containing Rb and other proteins, such as those with the unclear. In experiments with genetically engineered LXCXE motif, to a promoter. Still other binding sites mice lacking Rb, introduction of an Rb transgene with appear to be in the pocket. Whereas HDAC1 and HDAC2 an amino-terminal truncation mutation delayed the em- contain LXCXE-like motifs through which they can in- bryonic lethality caused by homozygous loss of Rb but teract with Rb (Magnaghi et al. 1998), HDAC3 does not did not prevent it, suggesting that this region may be contain this sequence, and mutations in the LXCXE important for complete Rb function during development binding site of Rb do not affect its binding to Rb (Chen (Riley et al. 1997). Similarly, this Rb mutant did not and Wang 2000; Dahiya et al. 2000). Although BRG1 con- prevent the development of pituitary tumors in Rb+/− tains an LXCXE, it does not require this sequence to bind mice, although the onset of tumors was delayed, suggest- Rb, which allows Rb to recruit BRG1 and HDAC1 into a ing that this region may play some role in Rb-mediated single complex (Zhang et al. 2000). Three recent studies tumor suppression (Riley et al. 1997). However, these in which the LXCXE-binding site was mutated have pro- experiments relied on expression of an Rb transgene that vided additional, albeit somewhat conflicting, insights may not entirely recapitulate the expression pattern and into its role. In each of these studies, the mutations in- protein level of endogenous Rb. In other experiments, hibited binding to E1A. In two of the studies the muta- tumor suppression by Rb was actually enhanced when tions also inhibited binding to HDAC1 and HDAC2 but the amino-terminal region was removed (Qin et al. 1992; did not affect binding to HDAC3, BRG1, and E2F1 (Chen Xu et al. 1994; Chow et al. 1996). Thus, a physiologic and Wang 2000; Dahiya et al. 2000). In the third study role of the amino-terminal region remains unclear and mutations did not affect binding to HDAC1 (N. Dyson, may only be settled once this region of the Rb gene is pers. comm.). Because mutation of the LXCXE-binding deleted in mice. site had variable effects on Rb function in these studies, further work is needed to clarify its role and to charac- Rb-mediated inhibition of E2F terize other binding sites on Rb. Another functional domain of Rb is located within the Rb can repress transcription by at least two different carboxy-terminal region. This region contains binding mechanisms. First, it can bind transcription factors such sites for the c-abl tyrosine kinase and MDM2, which as E2F and block their ability to activate transcription appear to be distinct from the E2F site in the carboxy- (Flemington et al. 1993; Helin et al. 1993). Second, the terminal region (Welch and Wang 1993; Xiao et al. 1995). Rb–E2F repressor complex that forms at promoters can The tyrosine kinase activity of c-abl is blocked when it is actively repress transcription (Bremner et al. 1995; Sell- complexed with Rb (Welch and Wang 1993). This inter- ers et al. 1995; Weintraub et al. 1995). The balance be- action appears to be important for Rb-mediated growth tween these two activities in vivo is still in question.
Load more

Recommended publications
  • Regulation of DNA Binding by Rel/NF-Kb Transcription Factors: Structural Views
    Oncogene (1999) 18, 6845 ± 6852 ã 1999 Stockton Press All rights reserved 0950 ± 9232/99 $15.00 http://www.stockton-press.co.uk/onc Regulation of DNA binding by Rel/NF-kB transcription factors: structural views Frances E Chen1 and Gourisankar Ghosh*,2 1Department of Biology, University of California ± San Diego, 9500 Gilman Drive, MC 0359, La Jolla, California, CA 92093-0359, USA; 2Department of Chemistry and Biochemistry, University of California ± San Diego, 9500 Gilman Drive, MC 0359, La Jolla, California, CA 92093-0359, USA Rel/NF-kB transcription factors form homo- and nuclear localization and IkB binding. Additional Rel/ heterodimers with dierent DNA binding site speci®cities NF-kB family members include the v-Rel oncoprotein and DNA binding anities. Several intracellular path- of the avian Rev-T retrovirus, and the Drosophila ways evoked by a wide range of biological factors and Dorsal, Dif and Relish proteins. Rel/NF-kB proteins environmental conditions can lead to the activation of bind to DNA segments with a consensus sequence of Rel/NF-kB dimers by signaling degradation of the 5'-GGGRNYYYCC-3' collectively referred to as kB inhibitory IkB protein. In the nucleus Rel/NF-kB dimers elements or kB sites. For the NF-kB p50/RelA modulate the expression of a variety of genes including heterodimer alone, there are a large number of those encoding cytokines, growth factors, acute phase dierent kB sites that display varying degrees of response proteins, immunoreceptors, other transcription consensus (Figure 1). factors, cell adhesion molecules, viral proteins and Rel/NF-kB regulation can occur at multiple levels: regulators of apoptosis.
    [Show full text]
  • Rela, P50 and Inhibitor of Kappa B Alpha Are Elevated in Human Metastatic Melanoma Cells and Respond Aberrantly to Ultraviolet Light B
    PIGMENT CELL RES 14: 456–465. 2001 Copyright © Pigment Cell Res 2001 Printed in Ireland—all rights reser6ed ISSN 0893-5785 Original Research Article RelA, p50 and Inhibitor of kappa B alpha are Elevated in Human Metastatic Melanoma Cells and Respond Aberrantly to Ultraviolet Light B SUSAN E. McNULTY, NILOUFAR B. TOHIDIAN and FRANK L. MEYSKENS Jr. Department of Medicine and Chao Family Comprehensi6e Cancer Center, Uni6ersity of California Ir6ine Medical Center, 101 City Dri6e South, Orange, California 92868 *Address reprint requests to Prof. Frank L. Meyskins, Chao Family Comprehensi6e Cancer Center, Building 23, Rte 81, Uni6ersity of California Ir6ine Medical Center, 101 City Dri6e South, Orange, California 92868. E-mail: fl[email protected] Received 20 April 2001; in final form 15 August 2001 Metastatic melanomas are typically resistant to radiation and melanocytes. We also found that melanoma cells expressed chemotherapy. The underlying basis for this phenomenon may higher cytoplasmic levels of RelA, p105/p50 and the inhibitory result in part from defects in apoptotic pathways. Nuclear protein, inhibitor of kappa B alpha (IkBa) than melanocytes. factor kappa B (NFkB) has been shown to control apoptosis in To directly test whether RelA expression has an impact on many cell types and normally functions as an immediate stress melanoma cell survival, we used antisense RelA phosphoroth- response mechanism that is rigorously controlled by multiple ioate oligonucleotides and found that melanoma cell viability inhibitory complexes. We have previously shown that NFkB was significantly decreased compared with untreated or con- binding is elevated in metastatic melanoma cells relative to trol cultures. The constitutive activation of NFkBin normal melanocytes.
    [Show full text]
  • REV-Erbα Regulates CYP7A1 Through Repression of Liver
    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2017/12/13/dmd.117.078105.DC1 1521-009X/46/3/248–258$35.00 https://doi.org/10.1124/dmd.117.078105 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 46:248–258, March 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics REV-ERBa Regulates CYP7A1 Through Repression of Liver Receptor Homolog-1 s Tianpeng Zhang,1 Mengjing Zhao,1 Danyi Lu, Shuai Wang, Fangjun Yu, Lianxia Guo, Shijun Wen, and Baojian Wu Research Center for Biopharmaceutics and Pharmacokinetics, College of Pharmacy (T.Z., M.Z., D.L., S.W., F.Y., L.G., B.W.), and Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research (T.Z., B.W.), Jinan University, Guangzhou, China; and School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China (S.W.) Received August 15, 2017; accepted December 6, 2017 ABSTRACT a Nuclear heme receptor reverse erythroblastosis virus (REV-ERB) reduced plasma and liver cholesterol and enhanced production of Downloaded from (a transcriptional repressor) is known to regulate cholesterol 7a- bile acids. Increased levels of Cyp7a1/CYP7A1 were also found in hydroxylase (CYP7A1) and bile acid synthesis. However, the mech- mouse and human primary hepatocytes after GSK2945 treatment. anism for REV-ERBa regulation of CYP7A1 remains elusive. Here, In these experiments, we observed parallel increases in Lrh-1/LRH- we investigate the role of LRH-1 in REV-ERBa regulation of CYP7A1 1 (a known hepatic activator of Cyp7a1/CYP7A1) mRNA and protein.
    [Show full text]
  • Original Article EP300 Regulates the Expression of Human Survivin Gene in Esophageal Squamous Cell Carcinoma
    Int J Clin Exp Med 2016;9(6):10452-10460 www.ijcem.com /ISSN:1940-5901/IJCEM0023383 Original Article EP300 regulates the expression of human survivin gene in esophageal squamous cell carcinoma Xiaoya Yang, Zhu Li, Yintu Ma, Xuhua Yang, Jun Gao, Surui Liu, Gengyin Wang Department of Blood Transfusion, The Bethune International Peace Hospital of China PLA, Shijiazhuang 050082, Hebei, P. R. China Received January 6, 2016; Accepted March 21, 2016; Epub June 15, 2016; Published June 30, 2016 Abstract: Survivin is selectively up-regulated in various cancers including esophageal squamous cell carcinoma (ESCC). The underlying mechanism of survivin overexpression in cancers is needed to be further studied. In this study, we investigated the effect of EP300, a well known transcriptional coactivator, on survivin gene expression in human esophageal squamous cancer cell lines. We found that overexpression of EP300 was associated with strong repression of survivin expression at the mRNA and protein levels. Knockdown of EP300 increased the survivin ex- pression as indicated by western blotting and RT-PCR analysis. Furthermore, our results indicated that transcription- al repression mediated by EP300 regulates survivin expression levels via regulating the survivin promoter activity. Chromatin immunoprecipitation (ChIP) analysis revealed that EP300 was associated with survivin gene promoter. When EP300 was added to esophageal squamous cancer cells, increased EP300 association was observed at the survivin promoter. But the acetylation level of histone H3 at survivin promoter didn’t change after RNAi-depletion of endogenous EP300 or after overexpression of EP300. These findings establish a negative regulatory role for EP300 in survivin expression. Keywords: Survivin, EP300, transcription regulation, ESCC Introduction transcription factors and the basal transcrip- tion machinery, or by providing a scaffold for Survivin belongs to the inhibitor of apoptosis integrating a variety of different proteins [6].
    [Show full text]
  • Nuclear Localization of DP and E2F Transcription Factors by Heterodimeric Partners and Retinoblastoma Protein Family Members
    Journal of Cell Science 109, 1717-1726 (1996) 1717 Printed in Great Britain © The Company of Biologists Limited 1996 JCS7086 Nuclear localization of DP and E2F transcription factors by heterodimeric partners and retinoblastoma protein family members Junji Magae1, Chin-Lee Wu2, Sharon Illenye1, Ed Harlow2 and Nicholas H. Heintz1,* 1Department of Pathology, University of Vermont, Burlington VT 05405, USA 2Massachusetts General Hospital Cancer Center, Charlestown MA 02129, USA *Author for correspondence SUMMARY E2F is a family of transcription factors implicated in the showed that regions of E2F-1 and DP-1 that are required regulation of genes required for progression through G1 for stable association of the two proteins were also required and entry into the S phase. The transcriptionally active for nuclear localization of DP-1. Unlike E2F-1, -2, and -3, forms of E2F are heterodimers composed of one polypep- E2F-4 did not accumulate in the nucleus unless it was coex- tide encoded by the E2F gene family and one polypeptide pressed with DP-2. p107 and p130, but not pRb, stimulated encoded by the DP gene family. The transcriptional activity nuclear localization of E2F-4, either alone or in combina- of E2F/DP heterodimers is influenced by association with tion with DP-2. These results indicate that DP proteins the members of the retinoblastoma tumor suppressor preferentially associate with specific E2F partners, and protein family (pRb, p107, and p130). Here the intracellu- suggest that the ability of specific E2F/DP heterodimers to lar distribution of E2F and DP proteins was investigated in localize in the nucleus contributes to the regulation of E2F transiently transfected Chinese hamster and human cells.
    [Show full text]
  • Cell Stress and MEKK1-Mediated C-Jun Activation Modulate NF B
    Molecular Biology of the Cell Vol. 13, 2933–2945, August 2002 Cell Stress and MEKK1-mediated c-Jun Activation Modulate NF␬B Activity and Cell Viability Isabel Sa´nchez-Pe´rez, Salvador Aznar Benitah, Montserrat Martı´nez-Gomariz, Juan Carlos Lacal, and Rosario Perona* Instituto de Investigaciones Biome´dicas Consejo Superior de Investigaciones Cientificas-Universidad Auto´noma de Madrid, 28029 Madrid, Spain Submitted January 15, 2002; Revised April 29, 2002; Accepted May 31, 2002 Monitoring Editor: Carl-Henrik Heldin Chemotherapeutic agents such as cisplatin induce persistent activation of N-terminal c-Jun Kinase, which in turn mediates induction of apoptosis. By using a common MAPK Kinase, MEKK1, cisplatin also activates the survival transcription factor NF␬B. We have found a cross-talk between c-Jun expression and NF␬B transcriptional activation in response to cisplatin. Fibroblast derived from c-jun knock out mice are more resistant to cisplatin-induced cell death, and this survival advantage is mediated by upregulation of NF␬B-dependent transcription and expression of MIAP3. This process can be reverted by ectopic expression of c-Jun in c-junϪ/Ϫ fibroblasts, which decreases p65 transcriptional activity back to normal levels. Negative regulation of NF␬B- dependent transcription by c-jun contributes to cisplatin-induced cell death, which suggests that inhibition of NF␬B may potentiate the antineoplastic effect of conventional chemotherapeutic agents. INTRODUCTION cis-Diaminedichloroplatinum (c-DDP, cisplatin) is a DNA- reactive agent commonly used in chemotherapy protocols in Induction of apoptosis is the primary mechanism of tumor the treatment of several kinds of human cancers. Lesions of cell killing by radiation and chemotherapeutic agents.
    [Show full text]
  • TP63 and TP73 in Cancer, an Unresolved В€Œfamily∕ Puzzle Of
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector FEBS Letters 588 (2014) 2590–2599 journal homepage: www.FEBSLetters.org Review TP63 and TP73 in cancer, an unresolved ‘‘family’’ puzzle of complexity, redundancy and hierarchy Antonio Costanzo a, Natalia Pediconi b,c, Alessandra Narcisi a, Francesca Guerrieri c,d, Laura Belloni c,d, ⇑ Francesca Fausti a, Elisabetta Botti a, Massimo Levrero c,d, a Dermatology Unit, Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Italy b Laboratory of Molecular Oncology, Department of Molecular Medicine, Sapienza University of Rome, Italy c Center for Life Nanosciences (CNLS) – IIT/Sapienza, Rome, Italy d Laboratory of Gene Expression, Department of Internal Medicine (DMISM), Sapienza University of Rome, Italy article info abstract Article history: TP53 belongs to a small gene family that includes, in mammals, two additional paralogs, TP63 and Received 19 May 2014 TP73. The p63 and p73 proteins are structurally and functionally similar to p53 and their activity as Revised 16 June 2014 transcription factors is regulated by a wide repertoire of shared and unique post-translational mod- Accepted 16 June 2014 ifications and interactions with regulatory cofactors. p63 and p73 have important functions in Available online 28 June 2014 embryonic development and differentiation but are also involved in tumor suppression. The biology Edited by Shairaz Baksh, Giovanni Blandino of p63 and p73 is complex since both TP63 and TP73 genes are transcribed into a variety of different and Wilhelm Just isoforms that give rise to proteins with antagonistic properties, the TA-isoforms that act as tumor- suppressors and DN-isoforms that behave as proto-oncogenes.
    [Show full text]
  • Retinoblastoma-Related P107 and Prb2/P130 Proteins in Malignant Lymphomas: Distinct Mechanisms of Cell Growth Control1
    Vol. 5, 4065–4072, December 1999 Clinical Cancer Research 4065 Retinoblastoma-related p107 and pRb2/p130 Proteins in Malignant Lymphomas: Distinct Mechanisms of Cell Growth Control1 Lorenzo Leoncini, Cristiana Bellan, ated according to the Kaplan-Meier method and the log- Antonio Cossu, Pier Paolo Claudio, Stefano Lazzi, rank test. We found a positive correlation between the per- Caterina Cinti, Gabriele Cevenini, centages of cells positive for p107 and proliferative features such as mitotic index and percentage of Ki-67(1) and cyclin Tiziana Megha, Lorella Laurini, Pietro Luzi, A(1) cells, whereas such correlation could not be demon- Giulio Fraternali Orcioni, Milena Piccioli, strated for the percentages of pRb2/p130 positive cells. Low Stefano Pileri, Costantino Giardino, Piero Tosi, immunohistochemical levels of pRb2/p130 detected in un- and Antonio Giordano2 treated patients with NHLs of various histiotypes inversely Institute of Pathologic Anatomy and Histology, University of Sassari, correlated with a large fraction of cells expressing high Sassari, Italy [L. L., A. C.]; Institute of Pathologic Anatomy and levels of p107 and proliferation-associated proteins. Such a Histology [C. B., S. L., T. M., L. L., P. L., P. T.] and Institute of pattern of protein expression is normally observed in con- Thoracic and Cardiovascular Surgery and Biomedical Technology tinuously cycling cells. Interestingly, such cases showed the [G. C.], University of Siena, Siena, Italy; Departments of Pathology, highest survival percentage (82.5%) after the observation Anatomy, and Cell Biology, Jefferson Medical College, and Sbarro Institute for Cancer Research and Molecular Medicine, Philadelphia, period of 10 years. Thus, down-regulation of the RB-related Pennsylvania 19107 [P.
    [Show full text]
  • A Dissertation Entitled the Androgen Receptor
    A Dissertation entitled The Androgen Receptor as a Transcriptional Co-activator: Implications in the Growth and Progression of Prostate Cancer By Mesfin Gonit Submitted to the Graduate Faculty as partial fulfillment of the requirements for the PhD Degree in Biomedical science Dr. Manohar Ratnam, Committee Chair Dr. Lirim Shemshedini, Committee Member Dr. Robert Trumbly, Committee Member Dr. Edwin Sanchez, Committee Member Dr. Beata Lecka -Czernik, Committee Member Dr. Patricia R. Komuniecki, Dean College of Graduate Studies The University of Toledo August 2011 Copyright 2011, Mesfin Gonit This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of The Androgen Receptor as a Transcriptional Co-activator: Implications in the Growth and Progression of Prostate Cancer By Mesfin Gonit As partial fulfillment of the requirements for the PhD Degree in Biomedical science The University of Toledo August 2011 Prostate cancer depends on the androgen receptor (AR) for growth and survival even in the absence of androgen. In the classical models of gene activation by AR, ligand activated AR signals through binding to the androgen response elements (AREs) in the target gene promoter/enhancer. In the present study the role of AREs in the androgen- independent transcriptional signaling was investigated using LP50 cells, derived from parental LNCaP cells through extended passage in vitro. LP50 cells reflected the signature gene overexpression profile of advanced clinical prostate tumors. The growth of LP50 cells was profoundly dependent on nuclear localized AR but was independent of androgen. Nevertheless, in these cells AR was unable to bind to AREs in the absence of androgen.
    [Show full text]
  • AP-1 in Cell Proliferation and Survival
    Oncogene (2001) 20, 2390 ± 2400 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc AP-1 in cell proliferation and survival Eitan Shaulian1 and Michael Karin*,1 1Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, University of California San Diego, 9500 Gilman Drive, La Jolla, California, CA 92093-0636, USA A plethora of physiological and pathological stimuli extensively discussed previously (Angel and Karin, induce and activate a group of DNA binding proteins 1991; Karin, 1995). that form AP-1 dimers. These proteins include the Jun, The mammalian AP-1 proteins are homodimers and Fos and ATF subgroups of transcription factors. Recent heterodimers composed of basic region-leucine zipper studies using cells and mice de®cient in individual AP-1 (bZIP) proteins that belong to the Jun (c-Jun, JunB proteins have begun to shed light on their physiological and JunD), Fos (c-Fos, FosB, Fra-1 and Fra-2), Jun functions in the control of cell proliferation, neoplastic dimerization partners (JDP1 and JDP2) and the closely transformation and apoptosis. Above all such studies related activating transcription factors (ATF2, LRF1/ have identi®ed some of the target genes that mediate the ATF3 and B-ATF) subfamilies (reviewed by (Angel eects of AP-1 proteins on cell proliferation and death. and Karin, 1991; Aronheim et al., 1997; Karin et al., There is evidence that AP-1 proteins, mostly those that 1997; Liebermann et al., 1998; Wisdom, 1999). In belong to the Jun group, control cell life and death addition, some of the Maf proteins (v-Maf, c-Maf and through their ability to regulate the expression and Nrl) can heterodimerize with c-Jun or c-Fos (Nishiza- function of cell cycle regulators such as Cyclin D1, p53, wa et al., 1989; Swaroop et al., 1992), whereas other p21cip1/waf1, p19ARF and p16.
    [Show full text]
  • Targeting the RB-E2F Pathway in Breast Cancer
    Oncogene (2016) 35, 4829–4835 © 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0950-9232/16 www.nature.com/onc REVIEW Targeting the RB-E2F pathway in breast cancer J Johnson1, B Thijssen1, U McDermott2, M Garnett2, LFA Wessels1 and R Bernards1 Mutations of the retinoblastoma tumor-suppressor gene (RB1) or components regulating the CDK-RB-E2F pathway have been identified in nearly every human malignancy. Re-establishing cell cycle control through cyclin-dependent kinase (CDK) inhibition has therefore emerged as an attractive option in the development of targeted cancer therapy. The most successful example of this today is the use of the CDK4/6 inhibitor palbociclib combined with aromatase inhibitors for the treatment of estrogen receptor- positive breast cancers. Multiple studies have demonstrated that the CDK-RB-E2F pathway is critical for the control of cell proliferation. More recently, studies have highlighted additional roles of this pathway, especially E2F transcription factors themselves, in tumor progression, angiogenesis and metastasis. Specific E2Fs also have prognostic value in breast cancer, independent of clinical parameters. We discuss here recent advances in understanding of the RB-E2F pathway in breast cancer. We also discuss the application of genome-wide genetic screening efforts to gain insight into synthetic lethal interactions of CDK4/6 inhibitors in breast cancer for the development of more effective combination therapies. Oncogene (2016) 35, 4829–4835; doi:10.1038/onc.2016.32; published online 29 February 2016 INTRODUCTION multi-subunit protein complex containing partner (DP), RB-like, To maintain genome integrity, the mammalian cell cycle must be E2F and MuvB (DREAM) represses most if not all cell cycle gene 6 stringently regulated.
    [Show full text]
  • Dialogue Between Estrogen Receptor and E2F Signaling Pathways: the Transcriptional Coregulator RIP140 at the Crossroads*
    Advances in Bioscience and Biotechnology, 2013, 4, 45-54 ABB http://dx.doi.org/10.4236/abb.2013.410A3006 Published Online October 2013 (http://www.scirp.org/journal/abb/) Dialogue between estrogen receptor and E2F signaling pathways: The transcriptional coregulator RIP140 at the * crossroads Marion Lapierre1,2,3,4, Aurélie Docquier1,2,3,4, Audrey Castet-Nicolas1,2,3,4, Stéphan Jalaguier1,2,3,4, Catherine Teyssier1,2,3,4, Patrick Augereau1,2,3,4, Vincent Cavaillès1,2,3,4 1IRCM—Institut de Recherche en Cancérologie de Montpellier, Montpellier, France 2INSERM, U896, Montpellier, France 3Université Montpellier1, Montpellier, France 4Institut Régional du Cancer Montpellier, Montpellier, France Email: [email protected] Received 25 July 2013; revised 25 August 2013; accepted 19 September 2013 Copyright © 2013 Marion Lapierre et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Estrogen Receptors; Gene Expression; Cell Proliferation; Breast Cancer; Endocrine Therapies Estrogen receptors and E2F transcription factors are the key players of two nuclear signaling pathways which exert a major role in oncogenesis, particularly 1. ESTROGEN RECEPTOR AND E2F in the mammary gland. Different levels of dialogue SIGNALING PATHWAYS between these two pathways have been deciphered 1.1. Estrogen Signaling in Breast Cancer Cells and deregulation of the E2F pathway has been shown to impact the response of breast cancer cells to endo- Estrogens are steroid hormones that regulate growth and crine therapies. The present review focuses on the differentiation of a large number of target tissues such as transcriptional coregulator RIP140/NRIP1 which is the mammary gland, the reproductive tract and skeletal involved in several regulatory feed-back loops and and cardiovascular systems [1].
    [Show full text]